MedTrace Logo

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

NCT04600284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-07-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.

Conditions

Interventions

DRUG

AD-2101

AD-2101 16/5mg

DRUG

AD-2102

AD-2102 25mg

DRUG

AD-2101 + AD-2102

AD-2101 16/5mg + AD-2102 25mg

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • HyeWon Chung · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2021-01-20
Completion
2021-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04600284 on ClinicalTrials.gov